SEC Form 4 · accession 0001209191-17-047430

IMMUNE DESIGN CORP. · IMDZ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Development Officer

Period of report

Aug 1, 2017

Accepted (ET)

Aug 3, 2017 · 5:06 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001437786

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 1, 2017	M	10,000	$1.31	A	33,054	D
Common Stock^F2	Aug 1, 2017	S	9,253	$11.4042	D	23,801	D
Common Stock^F3	Aug 1, 2017	S	747	$11.798	D	23,054	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Rt to Buy)^F4	$1.31	Aug 1, 2017	M	10,000	D	—	Dec 8, 2021	Common Stock	10,000	38,715	D

F1The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 7, 2017.
F2The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $10.70 to $11.65 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
F3The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $11.70 to $11.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
F4Fully vested and immediately exercisable.